AT04
/ AFFiRiS, Frontier Biotech
- LARVOL DELTA
Home
Next
Prev
1 to 2
Of
2
Go to page
1
May 11, 2021
A phase I study assessing the safety, tolerability, immunogenicity, and low-density lipoprotein cholesterol-lowering activity of immunotherapeutics targeting PCSK9.
(PubMed, Eur J Clin Pharmacol)
- P1 | "Although both AT04A and AT06 were safe and immunogenic, only AT04A demonstrated significant LDLc-lowering activity, justifying further development."
Clinical • Journal • P1 data • Dyslipidemia • Fatigue • Metabolic Disorders • Musculoskeletal Pain • Pain
December 08, 2017
Lipid-lowering interventions targeting proprotein convertase subtilisin/kexin type 9 (PCSK9): an emerging chapter in lipid-lowering therapy.
(PubMed, Drugs Context)
- "Thus, interventions targeting PCSK9 by reducing its expression may lead to significant reductions of LDL-cholesterol and possibly decrease cardiovascular risk. The present review aims to present and discuss the current clinical and scientific data pertaining to lipid-lowering interventions targeting PCSK9."
Journal • Review • Biosimilar
1 to 2
Of
2
Go to page
1